ロード中...
Identification of Potent CD19 scFv for CAR T Cells through scFv Screening with NK/T-Cell Line
CD19 is the most promising target for developing chimeric-antigen receptor (CAR) T cells against B-cell leukemic cancer. Currently, two CAR-T-cell products, Kymriah and Yescarta, are approved for leukemia patients, and various anti-CD19 CAR T cells are undergoing clinical trial. Most of these anti-C...
保存先:
| 出版年: | Int J Mol Sci |
|---|---|
| 主要な著者: | , , , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
MDPI
2020
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7730610/ https://ncbi.nlm.nih.gov/pubmed/33271901 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/ijms21239163 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|